Dibutyl phthalate (DBP)

Dibutyl phthalate (DBP) is a low-molecular-weight phthalate ester primarily utilized as a plasticizer to increase the flexibility and durability of polymers in various consumer products, including food packaging, cosmetics, and medical device coatings [13, 18]. While it is not a therapeutic target, DBP is recognized as a significant environmental endocrine disruptor that interferes with biological signaling by acting as an antagonist to the androgen receptor (AR) and a modulator of several other nuclear receptors, such as the aryl hydrocarbon receptor (AhR) and peroxisome proliferator-activated receptors (PPARs) [2, 4, 9]. Chronic exposure to DBP is strongly linked to reproductive and developmental health issues, often referred to as "phthalate syndrome," which is characterized by reduced testosterone production, cryptorchidism, and impaired sperm quality [5, 9, 19]. Additionally, DBP has been shown to inhibit human glycogen synthase kinase-3 beta (GSK-3β) and is associated with other adverse conditions such as asthma, obesity, and neurotoxicity [14, 15]. Due to these pervasive health risks and its environmental persistence, DBP is classified as a priority pollutant and is subject to strict regulation and restrictions in many countries, particularly regarding its use in children's products [13, 17].

Other names

Di-n-butyl phthalaten-Butyl phthalate1,2-Benzenedicarboxylic acid dibutyl esterBenzene-1,2-dicarboxylic acid dibutyl esterDibutyl benzene-1,2-dicarboxylate

Dibutyl phthalate acts as an environmental endocrine disruptor primarily by antagonizing the androgen receptor (AR) and modulating nuclear receptors like the aryl hydrocarbon receptor (AhR), estrogen receptors (ER), and peroxisome proliferator-activated receptors (PPARs). It also interferes with steroidogenesis by altering the expression of enzymes such as aromatase and has been shown to inhibit glycogen synthase kinase-3 beta (GSK-3β), thereby disrupting hormonal homeostasis and diverse cellular signaling pathways.